Executive Summary
Transseptal transcatheter mitral valve replacement for mitral annular calcification works mechanically and fails biologically: in the ENCIRCLE MAC Registry published in JACC, the SAPIEN M3 abolished mitral regurgitation in 98.5% of implanted patients at one year, yet 33.6% were dead or hospitalized for heart failure, with 21.1% all-cause mortality and 11.4% needing mitral reintervention. That is a 93-patient single-arm study in people already judged unsuitable for surgery or repair, so the comparator is medical therapy, not surgical replacement, and the registry cannot tell us which patients were helped. Separately, a PRO-TAVI subanalysis in JACC: Cardiovascular Interventions found that in the highest SYNTAX tertile, deferring PCI before TAVR produced death, MI, or stroke in 30.9% versus 14.8% with upfront PCI. Together these tighten the case for anatomic and physiologic selection over procedural availability.
- ENCIRCLE MAC reported 5.1% disabling stroke, 4.8% clinically significant LVOT obstruction, and 9.2% hemolysis requiring transfusion or reintervention at one year, a complication profile no surgical series would tolerate electively.
- A 242-study, 181,187-patient meta-analysis ranked SAPIEN 3 lowest for moderate-to-severe paravalvular leak (1.04%) and stroke (1.87%), ACURATE neo2 lowest for pacemaker (7.7%), with long-term data too sparse to pool.
- Leadless pacemakers after TAVR matched transvenous devices for implant success and survival across 10,809 patients, with shorter stay and fewer HF admissions in sensitivity analysis only, mostly observational data.
- M-TEER at a center without on-site cardiac surgery achieved 81.0% device success versus 72.1% at the surgical center using the same operators, but N=64 and non-inferiority was not established.
- A Japanese multicenter score using BMI, peak velocity, and LV end-diastolic diameter stratified LVEF normalization after TAVI from 15% to 71%, derived retrospectively in 177 patients.
What to watch: the next PRO-TAVI readout on complete versus culprit-only revascularization, which will determine whether the SYNTAX signal survives randomization rather than subgroup slicing.
Aortic Valve (TAVR/TAVI)
Coronary complexity, not the valve, drives early risk in TAVR patients with concomitant CAD. The PRO-TAVI SYNTAX subanalysis in JACC: Cardiovascular Interventions (466 patients, post hoc, hypothesis-generating) showed no overall difference in the primary composite and less bleeding with deferred PCI, but a doubling of death/MI/stroke in the highest SYNTAX stratum when PCI was deferred. Both ACC/AHA 2020 and ESC 2025 list severe CAD requiring surgical revascularization among the factors favoring SAVR plus CABG, and this subanalysis is the cleanest recent argument for taking that tilt seriously rather than defaulting to staged transcatheter care.
Device-level data arrived from two directions. [NOTABLE] The PROLONG-TAVR meta-analysis pooled 242 observational studies and confirmed what the registries have shown: paravalvular leak remains self-expanding territory, pacemaker remains the dominant complication, and stroke has not improved across valve generations. The authors abandoned their long-term analysis because durability reporting was too sparse to pool. ACC/AHA 2020 built its TAVI recommendations on data extending to roughly five years; ESC 2025 claims comparable structural valve deterioration against SAVR out to ten years. This meta-analysis's inability to pool long-term outcomes is the clearest evidence yet that the ESC's durability claim remains unverified, not settled. Annals of Thoracic Surgery added a retrospective multicenter current-generation SE versus BE comparison; retrospective, so hypothesis-generating. On the physiology side, invasive pacing studies in 46 patients showed force-frequency and relaxation-frequency reserve recovers immediately after TAVI, evidence that pressure-overload myocardial dysfunction is load-dependent and reversible.
Mitral Valve (MitraClip, PASCAL, TMVR)
MAC remains the graveyard of mitral intervention, and ENCIRCLE does not change that. [NOTABLE] The ENCIRCLE MAC Registry in JACC enrolled 364 screened patients and implanted 93, a 26% conversion rate that is itself the headline. Technical performance was excellent and symptom, KCCQ, and 6-minute walk gains were sustained. The outcome ledger is harder: 21.1% mortality, 19.4% HF hospitalization, 5.1% disabling stroke, 11.4% reintervention, and 2.3% valve thrombosis at one year. The accompanying JACC editorial frames this as a pathway, not a solution. ESC 2025 gives TMVI for degenerative MS with MAC a Class IIb at experienced centers only; ENCIRCLE supports that grade and does not justify upgrading it. No surgical arm existed, and contemporary surgical mitral replacement in true MAC carries comparable mortality, so the honest claim is symptom relief in a population with no alternative.
Against that, endoscopic secondary chordae transfer with asymmetric edge-to-edge repair in Barlow's disease showed what durable mitral surgery still looks like in anatomy that permits it. The no-on-site-surgery M-TEER registry (N=64, sequential eras, wide confidence intervals) is interesting but not yet a permission slip for network programs.
Tricuspid Valve (TriClip, TTVR)
No tricuspid outcome data today, which is itself notable given how fast this field is moving. The only tricuspid item is a case report of tricuspid valve endocarditis diagnosed by point-of-care ultrasound and managed with percutaneous vegetation debulking plus antibiotics in an intravenous drug user with MRSA bacteremia. Percutaneous debulking sits entirely outside guideline text. Neither ACC/AHA 2020 nor ESC 2025 addresses aspiration debulking for right-sided IE, and the surgical literature still favors valve repair or replacement with complete vegetation excision when embolic burden and sepsis persist, especially in patients likely to relapse. ESC 2025 moved transcatheter tricuspid treatment to Class IIa for high-risk symptomatic severe TR on the strength of TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II, while ACC/AHA 2020 is silent. That gap, plus the STS/ACC TVT Registry real-world TTVR data showing 3.1% 30-day mortality, is where the next US guideline revision will have to land.
Surgical vs. Transcatheter Comparisons
No head-to-head surgical versus transcatheter trial published today. The closest comparator question is ENCIRCLE, where the control group is absent by design: every enrolled patient had already been declined for surgical mitral replacement and for transcatheter repair. A 33.6% one-year death-or-HFH rate in that population tells us about disease severity as much as about the device. The Annals of Thoracic Surgery multicenter analysis compares SE against BE valves rather than TAVR against SAVR, which reflects where the field's attention has drifted. Worth restating from the guideline text: ACC/AHA 2020 keeps SAVR as Class I below 65, ESC 2025 raised that floor to 70, and both still put bicuspid anatomy, subaortic calcification, concomitant aortopathy, and severe CAD requiring CABG on the surgical side of the ledger. The PRO-TAVI SYNTAX signal reinforces the last of those.
Device & Technology
Pure native aortic regurgitation is still a device problem, not a technique problem. A 13-patient single-center series of the ScienCrown short-frame, fully recapturable self-expanding valve reported 100% technical success, 92.3% early safety, 7.7% pacemaker, and no moderate or severe residual AR at 30 days, with 12.9% mean oversizing and no predilatation. Thirteen patients, one center, 30 days. ESC 2025 gives TAVI for AR a Class IIb restricted to inoperable patients; ACC/AHA 2020 does not endorse it at all, and valve-sparing root replacement remains Class I in young patients with AR. Nothing here moves that.
Two modeling and biomarker items. A six-patient patient-specific finite element study (covered as virtual heart models predicting post-TAVR heart block) separated LBBB from no-LBBB cases by strain in the left bundle region, with self-expanding devices generating higher mean strain than balloon-expandable. Six patients is a proof of concept, not a risk tool. And a review of von Willebrand factor assays in prosthetic valve dysfunction correctly positions them as investigational adjuncts for discordant imaging, not surveillance.
Industry & Market
Transcatheter mitral repair market forecasts through 2035 continue to project demand growth on aging demographics and indication expansion, per an IndexBox forecast. The clinical caveat belongs next to the number: ENCIRCLE screened 364 patients to implant 93. Anatomic screen-failure rates in the 70% range are the governing constraint on TMVR volume, and no forecast model that treats MAC prevalence as addressable market survives contact with CT screening. Cardiac Wire's framing of SAPIEN M3 as promising for select patients is the accurate read.
Financial Analysis
Edwards outperformed peers in Monday trading per MarketWatch and sits up 10.3% over six months, which is the market pricing a mitral and tricuspid pipeline that ENCIRCLE just made more complicated and more credible at the same time. SAPIEN M3 is an Edwards program; the registry gives it a defensible clinical niche with a narrow funnel. The PROLONG-TAVR meta-analysis finding SAPIEN 3 lowest for PVL and stroke supports the aortic franchise that still carries the revenue.
Boston Scientific is the outlier, down 32.4% over six months and trading at the bottom of its 52-week range at $43.69, with the analyst target of $59.24 implying the sell side has not yet repriced whatever drove the drawdown. Abbott reports October 21 against $1.41 EPS and $12.99B revenue, with TriClip volume the structural heart line to watch given ESC 2025's Class IIa upgrade and the absence of a matching ACC/AHA recommendation in the US. Anteris fell 3.6% to A$8.78 and remains pre-revenue on DurAVR, with a single-analyst A$13.00 target that carries no consensus weight.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $86.24, down $0.21 (-0.24%); six-month change +$8.04 (+10.28%)
- Market cap $49.7B; trailing P/E 50.73, forward P/E 25.49; beta 0.86
- 52-week range $72.42 to $96.29; five-day range $83.22 to $87.26
- Analyst target $101.96 (range $84.00 to $110.00, 26 analysts); consensus buy
- Next earnings November 4, EPS estimate $0.74 on $1.68B revenue
- The ENCIRCLE MAC one-year data is the most consequential clinical item for EW this quarter: it establishes SAPIEN M3 as viable in a population with no alternative while documenting a screen-failure rate that caps addressable volume.
Medtronic (MDT)
- Close $94.82, up $0.59 (+0.63%); six-month change +$9.20 (+10.75%)
- Market cap $121.3B; trailing P/E 23.01, forward P/E 14.79; beta 0.57
- 52-week range $73.31 to $106.33
- Analyst target $104.40 (range $85.00 to $121.00, 25 analysts); consensus buy
- Next earnings November 17, EPS estimate $1.33 on $9.48B revenue
- The PROLONG-TAVR pooled finding that paravalvular leak stays higher with self-expanding valves is a persistent Evolut headwind, partly offset by Evolut PRO ranking among the lowest for major vascular complications and bleeding.
Abbott (ABT)
- Close $104.75, up $1.78 (+1.72%); six-month change +$3.90 (+3.87%)
- Market cap $181.2B; trailing P/E 33.68, forward P/E 17.27; beta 0.58
- 52-week range $81.97 to $132.03
- Analyst target $120.72 (range $103.00 to $135.00, 26 analysts); consensus strong buy
- Next earnings October 21, EPS estimate $1.41 on $12.99B revenue
- MitraClip and TriClip both benefit from the ESC 2025 upgrades (Class I for ventricular secondary MR, Class IIa for transcatheter tricuspid), while US reimbursement remains anchored to ACC/AHA 2020 language that has not caught up.
Boston Scientific (BSX)
- Close $43.69, up $0.69 (+1.62%); six-month change -$20.92 (-32.37%)
- Market cap $63.3B; trailing P/E 17.83, forward P/E 12.94; beta 0.57
- 52-week range $41.39 to $105.65, currently near the low
- Analyst target $59.24 (range $44.00 to $94.00, 29 analysts); consensus buy
- Next earnings October 28, EPS estimate $0.74 on $5.09B revenue
- ACURATE neo2 posted the lowest pooled pacemaker rate (7.7%) in the PROLONG-TAVR meta-analysis, a genuine differentiator that the share price is not currently rewarding.
Anteris Technologies (AVR.AX)
- Close A$8.78, down A$0.33 (-3.62%); six-month change +A$0.34 (+4.03%)
- Market cap A$0.9B; forward P/E -4.17 (pre-profitability)
- 52-week range A$5.20 to A$15.47
- Single-analyst target A$13.00; no consensus recommendation
- Valuation rests entirely on DurAVR pivotal execution and on whether a single-piece biomimetic leaflet design produces a durability signal that current THVs cannot show, which the PROLONG-TAVR authors just confirmed nobody can currently measure.
Market outlook: valve equities are trading on margin and macro, not on valve data. Edwards and Medtronic both up roughly 10% over six months while Boston Scientific lost a third of its value tells you the structural heart story is not the swing factor in any of these names. The clinical signal that should matter to investors is the one the PROLONG-TAVR authors could not deliver: pooled long-term durability. Until reporting standards force consistent SVD definitions and ten-year follow-up, the lifetime-management argument that ESC 2025 placed at the center of TAVI planning stays unresolved, and so does the question of how much of the sub-70 AS population transcatheter therapy can defensibly claim.
Clinical Trial Updates
TCTMD released a discussion of BHF PROTECT-TAVI with Rajesh Kharbanda and C. Michael Gibson on whether routine cerebral embolic protection reduces stroke in TAVI. The question matters more after PROLONG-TAVR, which found stroke rates essentially flat across valve generations at roughly 1.9% to 2.5%. If iterative device engineering has not moved stroke, embolic protection or procedural technique has to. On the mitral side, the no-on-site-surgery M-TEER comparison explicitly calls for prospective evaluation of network-based programs with formal surgical backup; that trial does not yet exist and should.
Social & Conference Highlights
The JACC editorial accompanying ENCIRCLE, titled "Coming Full Circle in Transcatheter Mitral Valve Intervention in MAC," came from Safi, Khera, and Tang and reads as measured rather than celebratory. That tone is the right one. A 98.5% MR reduction rate alongside 21.1% one-year mortality is the clearest illustration available of why procedural success and clinical success are different endpoints, and why single-arm registries in no-option populations should inform access, not enthusiasm.
The next move belongs to the US guideline writers. ESC 2025 already repositioned tricuspid intervention, secondary MR, and the TAVI age threshold while ACC/AHA 2020 holds the line; every week that gap persists, American practice drifts further from the document that governs it. Watch whether the PRO-TAVI SYNTAX signal and the ENCIRCLE screening funnel make it into that revision, or whether both get filed as hypothesis-generating and forgotten.